Anagram Therapeutics develops effective therapeutics for patients with Malabsorption Syndromes and Nutrient Metabolism Disorders caused by genetic mutations or enzyme deficiencies. These syndromes and disorders lead to deficient absorption or metabolization of specific fats, sugars, proteins, vitamins, or other important nutrients, which can cause severe GI symptoms, inflammation, reduced quality of life, and/or organ failure. Anagram Therapeutics is dedicated to creating breakthrough oral enzymes to treat disorders that currently have inadequate or no treatments.

Anagram Therapeutics

Founded: 2017
Location: Framingham, MA
Employee range: 1 - 10
Clinical stage: Clin0
Therapy area: Exocrine pancreatic insufficiency; malabsorption syndromes
Drug types: END, RAR
Lead product: ANG003
Funding: $8M Jan 2017

Drug notes:

About:

Jobs: